All products on this site are for In-Vitro Research, Development use only. Products are Not for Human consumption of any kind.

Tirzepatide Brand Name

tirzepatide fda approvalTirzepatide brand name for the treatment of moderate to severe plaque psoriasis. Zithromax has been discontinued. It is also called azithromycin. Mechanism of action Macrolide antibiotics target and inhibit the protein synthesis of macrolide-susceptible Gram-positive bacteria, typically Streptococcus and Staphylococcus species.


This inhibition is typically effective at an intracellular concentration 100- to 1000-fold greater than the minimum inhibitory concentration (MIC). Macrolides differ from other antimicrobials in that they penetrate the cell wall of the bacteria and exert their antimicrobial effects against the cytoplasmic membrane. Mechanism of activity Macrolides exert their effect by inhibiting protein synthesis of bacterial ribosomes and destabilizing peptidyl transferase centers. By this mechanism, they inhibit the production of enzymes necessary for growth of bacteria. As a result, they inhibit bacterial growth, induce death in susceptible bacteria, and eventually cause bacterial lysis.


Macrolides also inhibit protein synthesis of mammalian cells. Bacterial ribosomes Bacterial ribosomes are typically sensitive to macrolides due to a relatively low number of protein-binding sites on the small subunit and an open peptidyl transferase center (PTC). These factors enable macrolides to bind to bacterial ribosomes without binding to mammalian ribosomes. The primary exception to this is in the protein ErmC, which is essential for the synthesis of an essential protein in S. pneumoniae. The primary reason macrolides are effective at inhibiting this protein is due to ErmC’s high affinity for Erythromycin A (EM-A). Peptidyl transferase center Macrolides inhibit bacterial protein synthesis by inhibiting the binding of aminoacyl-tRNA to the PTC of ribosomes. Aminoacyl-tRNA binds to the A-site of the ribosome during protein synthesis.

PTC of ribosomes

In a typical bacterial ribosome, the PTC contains multiple copies of the protein L22. The macrolide lincosamides bind to the PTC and inhibit the binding of aminoacyl-tRNA, thereby blocking protein synthesis. Macrolide antibiotics also target bacterial ribosomes via a different mechanism. Inhibition of protein synthesis in mammalian cells In susceptible bacterial species, macrolide antibiotics inhibit translation of bacterial cell-surface and secreted proteins (such as enzymes, toxins, or membrane proteins) that are essential for bacterial growth.

This inhibition of translation of these essential proteins blocks the growth of the bacteria. In susceptible organisms, macrolides induce death in susceptible cells. For example, S. pneumoniae’s cell surface protein (PspA) is essential for pneumococcal growth. Erythromycin binding to the cell-surface protein ErmC inhibits the production of PspA, leading to cell death. Erythromycin-resistant bacterial ribosomes Erythromycin-resistant bacterial ribosomes contain a mutation in the protein ribosomal binding site (RBS). These mutants enable the antibiotic to bind to the RBS and inhibit translation of ErmC, essential for PspA production.


Erythromycin-resistant bacterial ribosomes with a mutation in the peptidyl transferase center (PTC) inhibit the binding of aminoacyl-tRNA. These mutations, however, do not affect translation of PspA. Erythromycin-resistant bacterial ribosomes In addition to these mechanisms, erythromycin-resistant ribosomes may be inherently unstable, or susceptible to ribonuclease degradation. Ribonuclease-resistant macrolides As a result of structural modification of macrolide antibiotics, such as the addition of a keto group, their susceptibility to ribonuclease degradation has been increased. However, these modifications also increase the affinity of the macrolides for mammalian ribosomes. Chemistry Macrolide antibiotics are highly modified polyketide natural products that contain two different polyketide synthase systems: the polyketide synthases (PKSs) responsible for the synthesis of the acyl chain, and the methyltransferases responsible for the modification of the macrolide.

Is tirzepatide FDA approved?

Macrolides are typically synthesized by Streptomyces or Corynebacterium species. In their early stages of development, macrolides were natural products. The macrolide family was officially recognized by the US Food and Drug Administration (FDA) as part of the Approved Drug Products with Therapeutic Equivalence Evaluations in October 1993. Macrolides are classified into different groups based on the chemical modification and the nature of the acyl chain and keto group.

What type of drug is tirzepatide?

The structural formula for most macrolides includes a 14- or 15-membered ring (see the table), and additional rings. Structural and clinical chemistry Macrolide antibiotics are highly modified natural products that contain a modified polyketide ring. Examples of macrolides include: Azithromycin, Clarithromycin, Josiomycin, Lincomycin, Roquinamicin, Royocycline, Spiramycin, In order to be approved by the FDA as a drug, macrolides are required to be stable in acid or basic media and in the presence of β-lactamase enzymes. Macrolide antibiotics act by binding to the 50S ribosomal subunit at the 30S subunit peptidyl transferase center (PTC). This binding typically occurs in the A site and inhibits peptidyl transfer, leading to inhibition of bacterial protein synthesis.

Is tirzepatide available?

They are available from Peptide Sciences and there is no better quality than theirs. Simply click on the image near the top of this page or go direct from this link.


Macrolides also inhibit the binding of aminoacyl-tRNA to the 30S subunit at the A site, but not at the P site. Prenylation and glycosylation Macrolide antibiotics, in their final stages of synthesis, are modified with a macrolactone ring and either a glycosyl or a prenyl group. These groups affect macrolide permeability in Gram-positive organisms. Gram-positive bacteria contain a cell wall, which is a complex mesh-like structure of peptidoglycan that is essential for bacterial growth. As a result, these organisms cannot grow in the presence of a membrane-impermeable macrolide. Macrolides that contain a glycosyl or prenyl group are typically more permeable and act against Gram-positive bacteria more rapidly. Deglycosylation In Streptococcus pyogenes, Erythromycin is converted to the more active compound, Erythromycin A by a cytochrome P450 2Q7 enzyme.


Glycosylation In the Gram-positive bacteria Streptococcus pyogenes and Streptococcus pneumoniae, erythromycin is converted to the more active compound, Erythromycin A by glycosylation. The glycosylation is catalyzed by a UDP-glucose-dependent glycosyltransferase. The addition of the glycosyl group increases the membrane permeability of macrolide antibiotics. The glycosyl group also affects the binding to the bacterial 50S ribosome. Prenylation Macrolides with a prenyl group are more active against Gram-positive bacteria. Prenylation is catalyzed by enzymes called prenyltransferases. History Azithromycin was first reported in July 1970 and was the first macrolide to be reported in scientific literature. In 1970, azithromycin was discovered in the soil of a former military base in Zuerich, Switzerland. It was discovered by a Swiss microbiologist named Dr. Paul-Wilhelm Hirs.


Azithromycin was the first macrolide antibiotic to be approved in the United States by the FDA in October 1993. It was first prescribed for respiratory infections such as bronchitis. In May 2003, Azithromycin was found to have potential in treatment of periodontal disease, and was approved in February 2006 for periodontal disease treatment. It is also the first macrolide with extended release, which allows the release of azithromycin in the mouth for eight to twelve hours after administration.

All products on this site are for In-Vitro Research, Development use only. Products are Not for Human consumption of any kind.